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Abstract
Three rationally designed glucose-platinum conjugates (Glc-Pts) were synthesized and their 
biological activities evaluated. The Glc-Pts, 1-3, exhibit high levels of cytotoxicity toward a panel 
of cancer cells. The subcellular target and cellular uptake mechanism of the Glc-Pts were 
elucidated. For uptake into cells, Glc-Pt 1 exploits both glucose and organic cation transporters, 
both widely overexpressed in cancer. Compound 1 preferentially accumulates in and annihilates 
cancer, compared to normal epithelial, cells in vitro.
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Platinum-based anticancer drugs are among the most widely used of all chemotherapeutic 
treatments. Three FDA-approved platinum anticancer drugs, cisplatin, carboplatin, and 
oxaliplatin, have been in the clinic for many years to treat a variety of cancers including 
testicular, ovarian, cervical, head and neck, non-small-cell lung, and colorectal.[1] Despite 
their success, platinum compounds have a number of deficiencies originating from a lack of 
tumor selectivity. Only a small fraction of the total administered platinum accumulates at the 
tumor site, resulting in sub-optimal drug concentration at the target. Moreover, accumulation 
of platinum in healthy tissue leads to undesired side effects including nephrotoxicity, 
myelosuppression, peripheral neuropathy, ototoxicity, and nausea.[1b, 2] These drawbacks 
need to be addressed when designing next generation platinum drugs. Novel strategies for 
introducing tumor-targeting properties into platinum anticancer drug candidates are 
therefore of great interest.[3]
In order to maintain cellular homeostasis, growth, and proliferation, cancer cells 
significantly increase glucose uptake and the flux of metabolites through glycolysis. This 
phenomenon, termed “the Warburg effect,” arises from mitochondrial metabolic changes 
and is one of the hallmarks of cancer.[4] GLUT1, the most common glucose transporter, is 
widely overexpressed in many human cancers including hepatic, pancreatic, breast, 
esophageal, brain, renal, lung, cutaneous, colorectal, endometrial, ovarian, and cervical.[5] 
High GLUT1 expression levels in tumor biopsy samples correlate strongly with poor 
prognosis. Moreover, several other glucose transporters including GLUT2, GLUT3, 
GLUT12 and SGLT1/2 are also overexpressed in certain types of cancer cells.[5–6] 
Therefore glycoconjugation becomes an appealing strategy for targeted delivery of 
anticancer drugs. The potential of this strategy in diagnosis and therapy has already been 
realized, but there is much room for improvement.[7]
Examples of glucose-platinum conjugates (Glc-Pts) in which the key structural features of 
the sugar unit are not perturbed, a prerequisite for optimal transporter recognition, and in 
which the sugar is linked to the platinum complex via a spacer are scarce.[8] Moreover, these 
previous studies fail to answer a crucial question in glycoconjugate development, are the 
conjugates actually taken up by the glucose transporters broadly expressed in cancer cells?
In the present work, we report the synthesis, cytotoxicity, and detailed characterization of 
the cellular uptake mechanism of three novel Glc-Pts 1–3 (Figure 1a). The design of these 
conjugates was guided by a recently published crystal structure of the bacterial xylose 
transporter XylE, a GLUT1 homolog.[9] Although a crystal structure of human GLUT1 has 
also recently been published,[10] in this latter study the protein was captured in the inward 
open configuration, as opposed to the outward open configuration that a platinum-glucose 
conjugate would encounter when attempting to enter the cell. The XylE structure with bound 
D-glucose, on the other hand, exhibits the protein in an outward-facing conformation. This 
structure reveals that all of the hydroxyl groups of D-glucose except that on C6 are involved 
in hydrogen-bonding interactions with various amino acid residues of the transporter. We 
hypothesized that modification at the C6 position of D-glucose should not, therefore, 
interfere with receptor binding. Previous reports have also suggested that the C6 position of 
D-glucose can tolerate various functional groups while retaining substrate specificity for, 
and internalization by, GLUT1.[11] In fact, C6-glucose conjugates of 4-nitrobenzofurazan, 
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ketoprofen, and indomethacin were reported to bind GLUT1 with even higher affinity than 
unmodified D-glucose.[11a, 11c, 12] This property is highly desirable for a glucose-drug/
fluorophore conjugate, which has to compete with the high level of glucose (~ 6 mM) in the 
blood.[13]
Initial docking studies using a DFT-optimized structure of the C6-glucose-platinum 
derivative 1 (Figure 1b and S17) suggested that this complex is capable of binding in the 
cavity of an outward open XylE. The orientation of the sugar moiety in the docked complex 
differs from that of the glucose unit bound in the crystal structure, but hydrogen-bonding 
interactions occur with Gln168, Gln288, Tyr298, and Gln175. These residues had all been 
identified as key glucose-binding units in the XylE structure and either interact directly with 
the bound D-glucose or indirectly via hydrogen-bonded water molecules.[9] Additionally, 
Thr28 is capable of interacting with the carboxylate ligand of the platinum moiety.
The synthesis of a C6-Glc-Pt compound has not, to our knowledge, been previously 
reported. We therefore had to establish feasible routes to Glc-Pts 1-3 (Scheme 1 and see SI 
for details). All new compounds were unambiguously characterized by NMR 
(1H, 13C, 195Pt) spectroscopy and electrospray ionization (ESI) mass spectrometry. The 
purity of the platinum complexes (1–4) was confirmed to be ≥95% by elemental 
microanalyses and analytical HPLC (Figure S1–S4).
The stability of this class of compounds in water and biological media was evaluated using 
compound 1. The rate of activation of platinum drugs by dissociation of the leaving group 
ligand(s) from the platinum center in the presence of biological nucleophiles follows the 
order dichloride (cisplatin) > oxalate (oxaliplatin) > malonate (carboplatin), suggesting high 
stability for Glc-Pt 1 because its leaving group ligand is similar to that of carboplatin.[14] 
Indeed we observed that 1 is highly stable in water as evidenced by no change in the 1H 
NMR spectrum of 1 after 72 h in D2O (Figure S18). In RPMI medium, which is used 
routinely for mammalian tissue culture, slow activation of 1 by the nucleophiles present in 
the medium was observed (Figure S19). This result is consistent with the previously 
reported activation of structurally similar platinum compounds by nucleophiles.[14a, 14b] No 
significant decomposition was noticed up to 8 h, and approximately 60% of 1 remained 
unchanged even after 24 h, suggesting that the compound is highly stable in biological 
media. As expected, the formation of 5 as a result of activation of 1 was confirmed by ESI-
mass spectrometry (Figure S20).
Cellular uptake studies in A2780, DU145 and A549 cells revealed that, of the three Glc-Pts, 
1 is taken up most efficiently (Figure S5). We also observed a consistent decrease in uptake 
with increasing length of the linker joining the glucose and platinum moieties. It has been 
proposed that, upon binding to substrate in its outward open conformation, the GLUT1 
transporter undergoes a conformational change in which the extracellular entrance to the 
cavity is occluded and an opening to the cytoplasmic side of the membrane forms, allowing 
the substrate to enter into the cell.[15] Steric hindrance caused by an overly long substrate 
could block this conformational change, and we propose that this phenomenon is responsible 
for our observation that glucose-platinum conjugates with longer linkers display reduced 
cellular uptake. In this respect, we note that when the structure of GLUT1 in the inward 
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open form is aligned with that of XylE in the outward open form into which the Glc-Pts 
have been docked, significant steric clashes are observed for 3 but not 1 (Figure S17).[9–10]
We next evaluated the cytotoxicity of 1–3 and their aglycone 4 against a panel of human 
cancer cells of different origin using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay, a standard assay for cytotoxicity evaluation. The IC50 
(concentration required to reduce 50% cell viability) values derived from dose-response 
curves are summarized in Table S1. The cytotoxicity of the Glc-Pt compounds is generally 
comparable to those of aglycone 4, but greater than that of cisplatin. Ovarian cancer A2780 
cells were the most sensitive to the Glc-Pt compounds (IC50 = 0.15–0.22 μM). The relatively 
tight distribution of IC50 values for 1–3 suggests that, whereas the length of the spacer 
between the glucose and platinum moieties significantly influences their cellular uptake, it is 
not the primary determinant of the IC50 values of these compounds.
Although the previously described cellular uptake and cytotoxicity data may appear 
inconsistent, it is important to note that, for technical reasons, these initial assays were 
performed on different time scales. We subsequently investigated the effect of incubation 
time on the outcomes of these assays. Whereas the Glc-Pts were designed to be taken up by 
facilitated diffusion, the passive diffusion of the aglycone 4 will be impacted significantly 
by its lipophilicity and consequent ability to traverse the cellular membrane. We found that, 
even though the lipophilicity of 4 is approximately one log P unit higher than that of 1 
(Figure S10a), the accumulation of 1 was significantly higher than that of 4 when cells were 
incubated with either compound for 8 h (Figure S11). This result highlights the importance 
of the glucose moiety of 1 in its cellular uptake. In contrast to the comparable activity of 1 
and 4 observed in the 72 h incubation MTT assay (Table S1 and Figure S13b), an 8 h 
incubation MTT assay revealed 1 to be more cytotoxic than 4 in both A2780 and DU145 
cells (Figure S12, S13a & S13b), which is again consistent with the observed cellular uptake 
differences between 1 and 4 in an 8 h assay (Figure S11). We propose that the initial rate of 
accumulation of 1 in cells is faster than that of 4, but that this protein-mediated transport 
becomes saturated at longer time scales. On the other hand, the passive uptake of 4 is slower 
but does not saturate. As a result, prolonged incubation with 4 allows the levels of cellular 
platinum accumulation and cytotoxcitity to approach that of 1. The difference in the cellular 
uptake between 1 and 4 diminishes with increased incubation time, monitored from 8 h to 17 
h (Figure S13c).
In order to obtain insight into possible subcellular targets of the Glc-Pts, we studied the 
intracellular distribution of 1 and 2 as representatives of this class of compound in A2780 
cells. As shown in Figure S6, detection of platinum in the nucleus points to nuclear DNA as 
one potential target.[1a] Analysis of DNA platination levels (Figure S7a) revealed that 1 and 
2 platinate nuclear DNA, the extent of which is 764 ± 57 Pt adducts/104 nucleotides for 1, 
483 ± 79 Pt adducts/104 nucleotides for 2, and 685 ±17 adducts/104 nucleotides for 
oxaliplatin, which was included as a positive control. Increases in the expression levels of 
γH2AX, phos-p53, and phos-CHK2, which are canonical DNA damage biomarkers,[16] were 
also observed when cells were treated with increasing concentrations of 1 or 2 (Figure S7b). 
As expected for DNA-targeting platinum compounds,[1a] cell cycle arrest at G2/M phase and 
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induction of apoptosis were observed when A2780 cells were treated with compounds 1 or 2 
and then analyzed by flow cytometry (Figure S8 & S9). Taken together, these results are 
consistent with the proposal that Glc-Pts target genomic DNA, the platination of which leads 
to apoptosis.
As described earlier, one crucial question in glycoconjugate chemistry is whether or not the 
sugar-conjugated molecule is actually transported by the targeted sugar transporters. To 
address this issue, we carried out a series of experiments to investigate the details of the 
mechanism by which 1-3 are taken up by cells. Glc-Pts 1–3 are very hydrophilic (log P ~ 
−2) rendering cellular internalization via passive diffusion through the cellular lipid 
membrane highly unlikely. Furthermore, the lack of correlation between the log P values 
and cellular uptake is consistent with a protein-mediated transport mechanism (Figure 
S10a). The ovarian cancer cell line A2780 was chosen to evaluate the cellular uptake 
mechanism of the Glc-Pts because of its high level of GLUT1 expression,[17] confirmed by 
immunoblotting analyses (Figure S10b). Cellular uptake was first monitored in the absence 
and presence of an exofacial GLUT1 inhibitor 4,6-O-ethylidene-α-D-glucose (EDG),[18] and 
the results are presented in Figures 2a and S14c. A 50% reduction in cellular uptake of 1 
was measured in the presence of 100 mM EDG. Under similar conditions, the reduction in 
the cellular uptake of 2 and 3 was 38% and 30%, respectively. The cellular uptake of 
cisplatin did not change significantly in the presence of the inhibitor. Because cisplatin can 
be taken up via passive diffusion, this result matches well with our expectations. The 
inhibitor did, however, cause a 24% decrease in the cellular uptake of the aglycone 4. 
Because energy-dependent organic cation transporters (OCTs) contribute, at least in part, to 
the cellular uptake of 4 (Figure 2d, vide infra), we propose that the differential uptake 
induced by the presence of EDG most likely arises from the energy-depleted conditions 
produced by glucose transport inhibition. The extent of cellular uptake inhibition of the Glc-
Pts in the presence of EDG is in the order 1>2>3 and this trend tracks with the cellular 
uptake of these compounds (Figure S5), providing further support for the proposal that the 
GLUT1 translocation efficiencies for C6-glucose conjugates decrease with increasing linker 
length. Cumulatively, these results suggest that the cellular uptake of 1 is not only superior 
to, but is also more glucose-transporter-specific than, that of either 2 or 3. As a consequence, 
only 1 was used in the subsequent cellular uptake experiments.
Similarly to co-treatment with EDG, a 50% reduction in the cellular uptake of 1 was 
observed when a structurally and functionally different glucose transport inhibitor, phloretin, 
was used (Figure S14b). Moreover, given that D-glucose is the main substrate of GLUT1 
and other glucose transporters, it should compete with and inhibit the protein-mediated 
uptake of the Glc-Pts. When probed, D-glucose, but not L-glucose, exhibited a weak but 
statistically significant (p < 0.01) inhibitory effect on the uptake of 1 (Figure 2b). The poor 
inhibitory effect (ca. 30% reduction in uptake) exerted by D-glucose can be attributed to the 
high binding affinity of 1 to glucose transporters, a phenomenon previously reported for 
other C6-glucose conjugates and GLUT1.[11b, 11c, 12] We also tested the effect of D-glucose 
on the cellular uptake of the aglycone 4 and found the uptake to be unaffected. Furthermore, 
in cytotoxicity assays carried out in the presence of EDG, the IC50 value of 1 increased 19-
fold (Figure 2c). We note that EDG does not affect the ability of 1 to platinate DNA in vitro 
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(Figure S16). In contrast to the results with 1, only a 6-fold increase in IC50 value was 
observed during cotreatment with the control aglycone 4 and EDG. The slight increase in 
IC50 value of 4 mirrors the observed decrease in cellular uptake of 4 in the presence of 
glucose transport inhibitors, which we attribute to energy depletion. In order probe Glc-Pt 
uptake through glucose transporters in an orthogonal manner, we capitalized on the fact that 
hypoxia causes stimulation of glucose transport and metabolism in cancer cells.[19] As 
shown in Figure S14a, cellular uptake of 1 increased by 50% when A549 cells were treated 
with the hypoxia-inducing agent cobalt(II) chloride.[20] No significant difference in the 
uptake of 4 was observed under similar conditions. In summary, the uptake assays support 
the hypothesis that glucose transporters, such as GLUT1, are at least partially involved in 
the cellular entry mechanism of 1.
It is well documented that organic cation transporter 2 (OCT2) plays important roles in the 
cellular accumulation and consequent cytotoxicity of platinum complexes containing the 
(1R,2R)-cyclohexane-1,2-diamine (DACH) ligand.[21] OCT2-mediated cellular uptake has 
been suggested as a leading factor responsible for the sensitivity of colorectal cancer to 
oxaliplatin.[21] Because the Glc-Pts reported here bear the chelating DACH ligand, we 
investigated the potential of 1 to undergo translocation via OCT2, a transporter 
overexpressed in certain types of cancer cells and tumor samples from patients.[21–22] 
Expression of OCT2 in a panel of cancer cell lines was confirmed by Western blotting 
analysis (Figure S10b). A2780 cells were incubated with 10 μM 1 for 8 h in the presence or 
absence of EDG and/or the OCT2 inhibitor cimetidine (Ctd); oxaliplatin was employed as a 
positive control. In the presence of EDG, uptake of 1 was reduced by 50%, whereas the 
uptake levels of 4 and oxaliplatin were reduced by only 25% and 30%, respectively (Figure 
2d). The OCT2 inhibitor Ctd reduces the uptake of the positive control compound 
oxaliplatin by 70%. Assays with Ctd revealed reductions of 45% and 35% in the cellular 
uptake of 1 and 4, respectively. These results support the involvement of OCT2 in the 
cellular internalization of both 1 and 4. The uptake of 1 was further decreased by 20% (p < 
0.001) following treatment with a mixture of EDG and Ctd, compared to treatment with Ctd 
alone. These results further confirm the involvement of glucose transporters in the cellular 
uptake of 1 and indicate that OCT2 facilitates the cellular accumulation of 1 as well.
An ideal anticancer compound should be selective for cancer cells over normal healthy cells, 
thereby mitigating undesired toxic side effects associated with chemotherapy. We therefore 
evaluated the selectivity of Glc-Pt 1 using DU145 prostate and A498 kidney cancer cells and 
matched normal prostate epithelial (RWPE2) and kidney epithelial (CCD1105 KIDTr) cells. 
Both of the cancerous cell lines have high levels of GLUT1 expression as compared to the 
normal epithelial cells (Figure S10b). Strikingly, as presented in Figure 3, the accumulation 
of 1 was significantly higher in the cancer cells as compared to the matched normal cells. 
Notably, the cellular uptake of 1 in DU145 cells is four-fold higher than RWPE2 cells, and it 
can be inhibited by the potent glucose transport inhibitor Cytochalasin B or the OCT2 
inhibitor Ctd (Figure S15), suggesting that the cognate transporters mediate, at least in part, 
the preferential uptake of 1 by cancer cells. Similarly, 1 reduced the viability of cancer cells 
more efficiently as compared to normal epithelial cells (Figure 3c and d).
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Given that neuronal cells express high levels of GLUT1 transporters, adverse off-target 
neurological effects could arise with these glycoconjugates. We therefore evaluated the 
cytotoxicity of 1 in a murine hippocampal derived Neuro-2A neuronal cell line, which is 
known to express the GLUT1 transporter,[23] using short (8 h) and long (72 h) term assay. 
As shown in Figure S21, 1 has several fold higher IC50 values in Neuro-2A cells (IC50 = 
13.6±0.7 μM and 2.3±0.3 μM at 8 h and 72 h, respectively) when compared to the most 
sensitive overian cancer A2780 cells (IC50 = 2.2±0.1 μM and 0.15±0.06 μM for 8 h and 72 h 
assays, respectively). This result indicates that 1 is much more potent in ovarian cancer cells 
compared to neuronal Neuro-2A cells in vitro. Encouragingly, neurotoxicity has not yet 
been observed in vivo for glycoconjugated drugs tested thus far.[7a] Moreover, no 
neurological adverse side effects were observed during a phase II clinical study of 
glufosamide, a glucose conjugated DNA alkylating agent ifosamide mustard.[24] Finally, we 
note that the significant body of work showing preferential accumulation of 18FDG in 
tumors, used to diagnose malignancies, underscores the potential of glucose to become a 
powerful molecular tag for targeting cancer cells.[7d, 25] [7a]
In summary, novel C6-Glc-Pts were rationally designed and synthesized, and their 
mechanism of uptake was evaluated. Genomic DNA was confirmed to be one of the 
intracellular targets of the Glc-Pts. Among the Glc-Pts investigated, 1 most readily 
translocates through glucose transporters. The translocation efficiency and subsequent 
cellular accumulation were reduced with increasing size of the conjugate linker. Strikingly, 
1 preferentially accumulates in and annihilates cancer cells while showing reduced 
accumulation and low toxicity in noncancerous cells in vitro. These results clearly 
demonstrate the potential of glycoconjugation for selective destruction of cancer cells by 
platinum compounds. To our knowledge, 1 represents the first glucose-platinum conjugate 
where a glucose-transporter-mediated cellular uptake mechanism has been rigorously 
established. Furthermore, in addition to glucose transporters, OCT2 was identified as an 
additional transporter involved in the protein-mediated transport of 1, demonstrating the 
potential of 1 to exploit these two transporters, commonly overexpressed on the surface of 
tumor cells.
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Figure 1. 
(a) Structures of Glc-Pts 1-3 and their aglycone 4. (b) The hydrogen-bonding interactions 
present in the docking model of 1 into XylE (PDB 4GBZ).[9] The protein is shown as grey 
ribbons with the sidechains of key residues depicted as sticks. Complex 1 is shown as sticks 
and polar hydrogen atoms are explicitly portrayed. Color code: N blue, O red, H white, C 
cyan, protein C grey, Pt purple. Hydrogen-bonding interactions are illustrated with dashed 
yellow lines.
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Figure 2. 
(a) Effect of GLUT1 inhibitor EDG on the cellular uptake of 1–4 and cisplatin (10 μM 
compounds, 17 h). (b) Effect of externally added D-glucose and L-glucose (10 μM 
compounds, 17 h). (c) Effect of EDG on the IC50 values (72 h assay). (d) Effect of EDG, 
Ctd, and their mixture on the cellular up-take of 1, 4 and oxaliplatin (10 μM compounds, 8 
h). All experiments were done in A2780 cells and cellular uptake in absence of inhibitor was 
normalized to 100%. Data represent the mean ± SD of at least three or more replicates. The 
asterisks denote differences are statistically significant (*p < 0.01, **p < 0.001), ns = not 
statistically significant.
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Figure 3. 
(a and b) Preferential accumulation of Glc-Pt 1 in prostate and kidney cancer cells as 
compared to matched normal epithelial cells (20 μM, 8 h). (c and d) Effect of Glc-Pt 1 on 
the viability of cancer and matched normal cells. The asterisks denote differences that are 
statistically significant (*p<0.001, **p<0.02, ***p<0.01, ****p<0.002).
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Scheme 1. 
Synthetic route for glucose-platinum conjugate 1.
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